DC2_Ostc inhibitors are a class of chemical compounds that are designed to selectively bind to and inhibit the activity of the enzyme DC2_Ostc, which stands for decarboxylase 2 ortholog sterol transporter. This enzyme plays a critical role in the biosynthesis and regulation of various sterols, which are essential components of cell membranes in many organisms, including humans. The inhibition of DC2_Ostc can affect the balance and distribution of sterols within the cell, which has a significant impact on cell membrane fluidity, integrity, and function. The precise mechanism by which DC2_Ostc inhibitors interact with their target enzyme involves the blockage of the enzyme's active site, preventing the attachment and subsequent transformation of its specific substrates.
The molecular design of DC2_Ostc inhibitors is characterized by their ability to mimic or compete with the natural substrates of the DC2_Ostc enzyme. These inhibitors are often structured to fit snugly into the enzyme's active site, which is the region of the enzyme where substrate binding and catalysis occur. The active site typically has a highly specific shape and electronic environment, which is why inhibitors must have a complementary structure to bind effectively. DC2_Ostc inhibitors may also interact with the enzyme through a variety of non-covalent interactions, such as hydrogen bonds, ionic interactions, and hydrophobic contacts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Blocks the first step of glycoprotein biosynthesis by inhibiting N-acetylglucosamine lipid carrier creation. This can impact OSTC by reducing substrate availability. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Inhibits mannosidase II, causing disruption in the trimming of oligosaccharides, indirectly affecting OSTC's downstream actions. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Inhibits glucosidases I and II, affecting glycoprotein processing and potentially OSTC function. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Manosidase I inhibitor, altering the N-glycosylation pathway and indirectly influencing OSTC. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
Impairs glycosylation by competing with glucose, potentially reducing substrates for OSTC. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Inhibits mannosidase I, which impacts N-glycosylation and therefore can influence OSTC function. | ||||||
Elvucitabine | 181785-84-2 | sc-214959 | 10 mg | $5500.00 | ||
Impairs the formation of complex N-glycans, impacting the substrate availability for OSTC. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Influences glucosidase, affecting N-glycan processing, which can alter OSTC function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts ER and Golgi function, influencing several cellular processes including N-glycosylation and, by extension, OSTC. | ||||||